Natera (NasdaqGS:NTRA) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsAlexey Aleshin - General Manager of Oncology and Chief Medical OfficerCasey Woodring - VP of Equity ResearchDaniel Markowitz - VP of Equity ResearchDoug Schenkel - Managing Director of Life Science Tools and DiagnosticsJohn Fesko - President and Chief Business OfficerMichael Brophy - CFORicki Levitus - Equity Research AssociateSolomon Moshkevich - President of Clinical DiagnosticsSteve Chapman - CEOConference Call ...

Veracyte (NasdaqGM:VCYT) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Speaker12Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Shayla Gorman, Senior Director, Investor Relations. Please go ahead.Good afternoon, everyone. Thank you for joining us today for a discussion of our fourth quarter and full year 2025 financial results. With me today are Marc Stapley, Veracyte's Chief Executive Officer, and Rebecca Chambers, ...

Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $210 million, exceeding the high end of the pre-announced range, with a year-over-year growth of approximately 4% when excluding the impact from UnitedHealthcare's decision on GeneSight [6][25] - For the full year 2025, revenue was $824.5 million, with adjusted EBITDA of $14.3 million and adjusted EPS of $0.04, reflecting strong operational performance [8][28] - Adjusted gross margin for the fourth quarter was 70%, with adjusted operating expenses decreasing by $7 million year-over-year due to disciplined cost management [8][27] Business Line Data and Key Metrics Changes - Oncology revenue for the fourth quarter was $84.7 million, growing 2% year-over-year, with MyRisk test volume growth of 14% in the affected market and 11% in the unaffected market [16][18] - Prolaris revenue growth accelerated to 16% year-over-year in the fourth quarter, driven by 12% volume growth [16][17] - Women's health revenue was $88.5 million, an increase of 2% year-over-year, with hereditary cancer testing in the unaffected market growing by 3% and volume growth of 11% [18][19] - GeneSight revenue was $36.6 million, with volume growth of 9% year-over-year, despite challenges from UnitedHealthcare's coverage policy change [22][24] Market Data and Key Metrics Changes - The company served over 55,000 healthcare providers and delivered over 1.5 million test reports in 2025, indicating strong market penetration [8] - The mental health business saw a record number of ordering clinicians, exceeding 38,000 in the fourth quarter [22] Company Strategy and Development Direction - The company is focusing on high-growth market segments and plans multiple product launches, including the expanded MyRisk panel and the AI-enhanced Prolaris test [5][10] - The strategy includes strengthening commercial capabilities and expanding the sales team, with an investment of over $35 million to enhance organizational efficiency and growth [15][61] - The company aims to maintain leadership in urinary cancer testing while expanding into other cancer testing applications [9][33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving high single-digit to low double-digit growth rates in 2027 and beyond, supported by new product launches and recovery in the prenatal business [39][40] - The company is optimistic about the potential for continued momentum in hereditary cancer testing and prenatal testing, with expectations for recovery in 2026 [20][21] Other Important Information - The company plans to simplify its reporting structure to align with its strategic focus areas, including cancer care continuum, prenatal health, and mental health [31][32] - The company is preparing for the commercial launch of Precise MRD for breast cancer, with an alpha launch starting next week [11][14] Q&A Session Summary Question: Confidence in long-term growth rate - Management highlighted the drivers of growth for 2026, including product launches and improvements in commercial execution, expressing confidence in returning to high single-digit growth rates [37][39] Question: MRD launch strategy - Management indicated a selective approach for the MRD launch, focusing on user experience and operational efficiency before expanding volume [40][42] Question: Prenatal growth expectations - Management acknowledged a decline in prenatal volume in Q1 but anticipated recovery in Q2 and beyond, supported by a focused sales team and new product launches [45][81] Question: Prolaris momentum and dynamics - Management noted that improved engagement with KOLs and expansion of the sales team contributed to Prolaris growth, while also acknowledging potential favorable comparisons in Q4 [74][76] Question: Customer impact from order management issues - Management emphasized the importance of addressing order management issues and expressed confidence in restoring customer relationships and achieving growth moving forward [86][88]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $281 million, representing a 39% year-over-year growth, while full-year revenue reached $982 million, a 33% increase year-over-year [9][31] - Non-GAAP gross margin improved to 66% in Q4 2025, up from 63% in the prior year, driven by a significant reduction in Reveal cost per test [32] - Adjusted EBITDA loss improved to $64.9 million in Q4 2025, compared to $78.4 million in the prior year quarter [34] Business Line Data and Key Metrics Changes - Oncology revenue increased 30% to $190 million in Q4 2025, with oncology volumes growing 38% to approximately 79,000 tests [9][29] - Screening revenue totaled $35 million from approximately 38,000 Shield tests in Q4 2025, reflecting strong sequential growth [19][30] - Biopharma and data revenue grew 18% year-over-year to $210 million in 2025 [16][17] Market Data and Key Metrics Changes - Guardant360 Liquid volumes increased nearly 30%, supported by expanding clinical utility from SMART apps launched over the past year [30] - Reveal continued to be the fastest-growing oncology product, benefiting from CRC surveillance reimbursement and early uptake for late-stage therapy response monitoring [12][30] - Shield's adherence rate reached 93% across the first 100,000 tests ordered, significantly higher than other screening modalities [22] Company Strategy and Development Direction - The company aims to expand its multi-cancer detection capabilities with Shield, which now includes a multi-cancer detection result report [24] - Strategic collaborations with Quest Diagnostics and PathGroup are expected to broaden national reach and enhance commercial infrastructure [23] - The acquisition of MetaCyte Diagnostics is anticipated to enhance the oncology product portfolio and accelerate the multi-disease detection pipeline [28] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about continued strong growth in oncology, expecting 25%-27% revenue growth in 2026, supported by volume growth of approximately 30% [37] - The company anticipates free cash flow positive status for the core business in 2026, with a commitment to achieving company-wide cash flow breakeven by the end of 2027 [35][36] - Management highlighted the importance of reimbursement wins for therapy monitoring as a significant growth driver for the oncology business [46] Other Important Information - The company has established a robust pipeline of ongoing companion diagnostics programs, with 25 approvals to date across the U.S., Japan, and Europe [17] - The company expects to launch several new products in oncology, including Guardant360 Liquid CDx for lung FDA approval and Reveal Ultra [40] Q&A Session Summary Question: Can you elaborate on Reveal therapeutic monitoring and its opportunity? - Management expressed excitement about Reveal for therapy monitoring, emphasizing its synergy with Guardant360 for monitoring patient responses to therapies [44][46] Question: How should we think about the growth of oncology products throughout the year? - Management is bullish about 2026, expecting at least 20% growth in Guardant360 volumes and strong performance from Reveal [50][51] Question: What is the expected burn for Shield and the pacing of rep hiring in 2026? - The company anticipates a similar burn for screening as in 2025, around $220 million, while continuing to build out the commercial organization [54][56] Question: What is the latest thinking on ADLT pricing for Guardant360? - Management indicated that no ADLT pricing is baked into the 2026 guidance, with expectations for FDA submission in the second half of the year [60][61] Question: Can you discuss the opt-in rate for MCED Shield and potential FDA submission? - Management reported good adoption rates for the MCED offering, with enthusiasm from providers and patients, but did not disclose specific numbers [78]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $190 million, representing an 11% year-over-year growth, while full-year revenue reached $727 million, a 10% increase over 2024 [8][23] - Adjusted gross profit improved by $5.8 million, or 7% year-over-year, with adjusted EBITDA at $13.4 million, up 10% [20] - Cash flow from operations was positive at $1 million for Q4, with total cash at $160 million, slightly down from Q3 [22] Business Line Data and Key Metrics Changes - Clinical business revenue increased by 16% year-over-year in Q4, driven by effective commercial strategies and a 23% growth in NGS revenue [8][20] - Non-clinical revenue declined by over 25% in Q4, consistent with expectations [20] - Average revenue per clinical test (AUP) increased by 5% year-over-year, with a sequential increase of 3% from Q3 [21] Market Data and Key Metrics Changes - The company holds a leadership position in the hematology testing market with over 25% share across diagnostics and therapy selections [10] - Approximately 40% of active pathologists and oncologists ordered five or more tests from the company during the year, indicating significant market penetration [11] Company Strategy and Development Direction - The company aims to drive growth through strategic investments in NGS and MRD initiatives, with a focus on expanding its oncology sales force [29] - The launch of the RaDaR ST MRD assay is set for the end of the month, with plans to expand the sales force to penetrate the head and neck market [13][14] - The company is also focusing on enhancing operational efficiencies through technology and automation investments [22][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue growth in 2026, projecting revenues between $793 million and $801 million, with a focus on high-margin modalities [25][27] - The company anticipates modest revenue contributions from RaDaR ST in 2026, with expectations for accelerated growth in 2027 and beyond [14][25] - Management acknowledged potential impacts from extreme weather on Q1 volumes but remains optimistic about meeting full-year guidance [26] Other Important Information - The company has submitted additional solid tumor cancer indications for MolDX approval, which could double the market opportunity for RaDaR ST testing [14] - The PanTracer portfolio is expanding, with strong growth in PanTracer Tissue tests and the recent launch of PanTracer Pro [17] Q&A Session Summary Question: Can you provide specifics on the RaDaR ST launch and sales rep expansion? - Management confirmed the full launch of RaDaR ST at the end of the month, focusing on head and neck and breast cancer indications, with an initial expansion of sales reps dedicated to these areas [34][38] Question: What is the impact of exiting low-value business on clinical volume? - Management indicated that exiting low-value contracts would lead to higher AUP growth, with expectations for AUPs in the upper single-digit range and volume growth in the lower- to mid-single-digit range [45][46] Question: What are the expectations for pharma ordering in 2026? - Management anticipates modest erosion in the pharma business for 2026, with RaDaR ST expected to be a key growth driver [70][74] Question: Can you discuss the LIMS rollout and its impact on earnings? - The LIMS integration is ongoing, with benefits expected to materialize in 2027 and 2028, while operational efficiencies will begin to show in 2026 [60][62]

NeoGenomics FY Conference Summary Company Overview - **Company**: NeoGenomics (NasdaqCM:NEO) - **Industry**: Oncology diagnostics and lab services - **Focus**: Pure play in cancer testing, providing diagnostic services exclusively for oncology [4][5] Key Points and Arguments Market Position and Growth - NeoGenomics has established a market leadership position in hematology diagnostics, accounting for over **25%** of HEME testing across diagnostics and therapy selection [11] - The company has delivered **double-digit revenue growth** and **nine consecutive quarters** of positive adjusted EBITDA through Q3 of 2025 [5] - The oncology testing market is projected to grow significantly, with **one in two men** and **one in three women** expected to develop cancer in their lifetime [5][6] - NeoGenomics is poised to enter the **$20 billion-plus MRD market** with the launch of RaDaR-ST, which is expected to drive growth in 2026 and beyond [9][13] Strategic Pillars for Success 1. **Leverage Leadership in HEME**: Expand into solid tumor therapy selection and MRD markets [10] 2. **Evolve Offerings**: Meet the needs of pathologists and oncologists in community settings [10] 3. **Targeted Investments**: Drive top-line growth and margin expansion [10][17] Product Development and Launches - The company launched the **PanTracer family** for therapy selection, which has seen rapid growth in volumes, doubling from 2023 to 2024 and again from 2024 to 2025 [12] - RaDaR-ST has two approved indications for MolDX reimbursement, with additional submissions expected to double the patient eligibility for monitoring [13] - The introduction of **PanTracer liquid biopsy** is anticipated to follow a similar growth trajectory as the tissue assay, addressing gaps in the portfolio [36] Financial Performance - Preliminary Q4 revenue for 2025 is estimated at **$190 million**, representing **11% growth** year-over-year, with full-year revenue around **$727 million**, reflecting **10% growth** [21] - NGS revenue growth is projected at **22%** in 2025, indicating strong demand for next-generation sequencing products [18] Community Focus - Approximately **80%** of cancer treatment occurs in community settings, where NeoGenomics aims to provide NCI-level care through exceptional diagnostic testing [6][7] - The company has a **Net Promoter Score of 78**, indicating strong physician satisfaction and commitment to improving customer experience [14] Future Outlook - Growth drivers for 2026 include continued penetration of NGS, the launch of RaDaR-ST, and expansion into the northeast region through the acquisition of Pathline [22][23] - The company anticipates a balanced revenue contribution from both clinical and pharma segments, with a focus on clinical growth in the coming years [33] Additional Important Insights - NeoGenomics is focused on operational excellence, with a clear framework for product launches and customer engagement [31] - The partnership with Adaptive for heme MRD products is expected to enhance the portfolio and customer perception [41][42] - The company is preparing for the maturity of its **2028 convertible notes**, with plans to execute a strategy in 2026 [45][46] This summary encapsulates the key insights from the NeoGenomics FY Conference, highlighting the company's strategic focus, market position, and growth potential in the oncology diagnostics sector.

Summary of Guardant Health FY Conference Call Company Overview - **Company**: Guardant Health (NasdaqGS:GH) - **Industry**: Liquid biopsy and cancer diagnostics - **Mission**: To provide patients with more time free from disease through innovative cancer testing solutions [2][4] Key Financial Performance - **2025 Revenue**: $981 million, representing a 33% year-over-year growth - **Q4 2025 Revenue**: $280 million, a 39% year-over-year growth - **Oncology Testing Volumes**: 276,000 tests in 2025, a 34% year-over-year growth [4][9][33] Product Portfolio and Innovations - **Guardant360**: Leading liquid biopsy test for therapy selection, with nearly 30% growth in Q4 2025 - **Guardant Reveal**: Fastest-growing product, significant traction in minimal residual disease (MRD) monitoring - **Shield**: Blood-based colorectal cancer (CRC) screening test, showing strong adoption and a 93% adherence rate among patients [4][19][22][23] Market Opportunities - **Oncology Market**: Estimated total addressable market (TAM) of $30 billion in the U.S. - Liquid therapy selection: $10 billion TAM - MRD monitoring: $20 billion TAM [8][9] - **Colorectal Cancer Screening Market**: $50 billion with over 54 million unscreened patients in the U.S. [19][22] Strategic Developments - **Partnerships**: Collaborations with Quest Diagnostics and PathGroup to expand market reach - **Reimbursement Progress**: Secured ADLT status for Shield, improving Medicare pricing to $1,495 [20][24][25] - **AI Integration**: Infinity AI learning engine enhances clinical navigation and decision-making for physicians [10][11] Future Growth Drivers - **Product Launches**: Upcoming products include Guardant360 Liquid, ESR1 monitoring test, and Reveal Ultra - **Expansion Plans**: Focus on expanding self-pay Shield options and international markets [30][43] - **Clinical Evidence**: Over 1,200 conference publications and 670 peer-reviewed publications supporting technology efficacy [12] Financial Outlook - **Cash Position**: Approximately $1.3 billion in cash, with plans to reach free cash flow breakeven by Q4 2027 - **Investment Strategy**: Potential for small acquisitions to enhance technology and product differentiation [29][44] Additional Insights - **Patient Impact**: Real-world examples demonstrate the effectiveness of tests in early detection and treatment guidance [3][4] - **Market Dynamics**: The company is positioned to capitalize on the growing demand for non-invasive cancer screening and monitoring solutions [19][41] This summary encapsulates the key points from the Guardant Health FY Conference Call, highlighting the company's performance, product innovations, market opportunities, and strategic direction.

Financial Data and Key Metrics Changes - The company is tracking towards an Adjusted Free Cash Flow guidance of 25%-30% of Adjusted EBITDA for the full year, despite a hiccup in Q3 due to system conversion delays [10][11] - The long-term target for cash flow is to reach 50% of Adjusted EBITDA by 2027, with expected progress in 2026 [11] - Total revenue growth, excluding COVID and donor screening revenue, was reported at 5% for the quarter and year-to-date [15][16] Business Line Data and Key Metrics Changes - The Labs business grew at 4% in constant currency, while Immunohematology and Triage grew at 5% and 7% respectively, indicating solid performance across the base business [15][16] - The immunoassay to integrated analyzer ratio has improved from 25% to 30%, with a target of reaching 50% in the future, which is expected to enhance margins [22][23] Market Data and Key Metrics Changes - The Chinese market is expected to grow at a mid-single digit rate for the full year 2025, with the company feeling optimistic about opportunities despite previous reimbursement issues [29][32] - The immunohematology business holds the number one market position globally, with a growth rate of 5% in Q3, although Q4 growth may be lower due to shipment timing [33] Company Strategy and Development Direction - The company is focusing on optimizing its portfolio by exiting the U.S. donor screening market, which is expected to improve margins once fully wound down [39][40] - The strategy includes enhancing the integrated analyzer base to drive higher-margin immunoassay revenue, with a long runway for growth in this area [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving mid-single digit growth in the Labs and Immunohematology segments, with expectations for stable performance in the face of market challenges [15][16][29] - The company anticipates a good Q4 and is optimistic about the overall market dynamics, particularly in China and the point-of-care segment [29][41] Other Important Information - The company has achieved $140 million in cost savings since mid-2024, primarily through staffing reductions and indirect procurement initiatives [62] - The leverage ratio at the end of Q3 was reported at 4.4, with a target to reduce it to 2.5-3.5 times by early 2027 [70][71] Q&A Session Summary Question: Feedback from investors post-Q3 earnings call - Management noted that the stock reaction was perplexing, attributing it to high short interest, put option exposure, and cash flow timing issues related to ERP conversions [7][10] Question: Cash flow guidance and visibility - The company confirmed that cash flow guidance remains unchanged, with expectations for a strong Q4 as cash receipts from Q3 are collected [10][12] Question: Growth drivers in the Labs business - The Labs business is expected to maintain a mid-single digit growth trajectory, supported by consistent win rates and a stable contract structure [16][18] Question: Competitive dynamics in China - Management indicated that the company has been less affected by Chinese government actions compared to competitors, expecting mid-single digit growth in the Chinese market [28][32] Question: Margin improvement initiatives - The company is targeting 100-200 basis points of margin improvement in 2026, contingent on continued mid-single digit growth in the base business [62][65] Question: Future of the LEX acquisition - The company expects to complete the acquisition of LEX following FDA approval, with a limited commercial rollout anticipated in the first half of 2026 [51][56]

Financial Data and Key Metrics Changes - The company expects organic revenue growth to be in the range of 4.5%-5% for the full year, with year-to-date organic revenue growth at 4.8% [27] - Operating margin rates are growing from last year, with an expectation of expansion between 75 and 150 basis points over the next three years [31][32] Business Line Data and Key Metrics Changes - The consumer channel is growing at approximately 35% year-over-year, approaching $100 million in revenue [8] - Advanced diagnostics testing areas are growing in the low double digits, contributing close to $1 billion [12] Market Data and Key Metrics Changes - The company has gained access to new markets, including four states with a new payer, which is driving higher utilization [3] - The consumer segment is expanding as patients take more ownership of their health, contributing to increased testing [4] Company Strategy and Development Direction - The company is focusing on partnerships and collaborations to enhance its consumer testing offerings, such as with WHOOP and Oura [10] - Project Nova is expected to incur one-time costs between $250-$310 million over the next six to seven years, with anticipated benefits starting in 2027 [42][50] Management's Comments on Operating Environment and Future Outlook - Management is optimistic about the potential delay of PAMA, which could positively impact revenue [53] - The company is confident in its growth momentum, driven by utilization, consumer engagement, and advanced diagnostics [137] Other Important Information - The company is preparing for potential impacts from the expiration of ACA subsidies, estimating a 30 basis point impact on volumes and revenue next year [70] - The company is also focused on evidence generation and operational rigor to drive adoption of new tests like Haystack [91] Q&A Session Summary Question: Can you discuss the consumer channel and its growth? - The consumer channel is growing nicely, with expectations of reaching $250 million in revenue in the future, currently growing at 35% year-over-year [8] Question: How is the advanced diagnostics segment performing? - Advanced diagnostics testing areas are growing in the low double digits, contributing significantly to overall revenue [12] Question: What are the expectations for Project Nova? - Project Nova is expected to incur costs of $250-$310 million, with benefits anticipated starting in 2027 [42][50] Question: How does management view the potential impact of PAMA? - Management is optimistic about a potential delay in PAMA, which could help avoid a $100 million impact [53][60] Question: What are the key growth drivers for the company? - Key growth drivers include strong utilization, consumer momentum, and advanced diagnostics offerings [137]

Financial Data and Key Metrics Changes - The company expects organic revenue growth to be in the range of 4.5%-5% for the full year, with year-to-date organic revenue growth at 4.8% [27] - Operating margin rates are growing from last year, with an expectation of expansion between 75 and 150 basis points over the next three years [31][32] Business Line Data and Key Metrics Changes - The consumer channel is growing at approximately 35% year-over-year, approaching $100 million in revenue [8] - Advanced diagnostics testing areas are growing in the low double digits, contributing close to $1 billion [12] Market Data and Key Metrics Changes - The company has gained access to new markets, including four states with a new payer, which is driving higher utilization [3] - The consumer segment is expanding as patients take more ownership of their health, contributing to increased testing [4] Company Strategy and Development Direction - The company is focusing on partnerships and collaborations to enhance its consumer testing offerings, such as with WHOOP and Oura [10] - Project Nova is expected to incur one-time costs between $250-$310 million over the next six to seven years, with anticipated benefits starting in 2027 [42][50] Management's Comments on Operating Environment and Future Outlook - Management is optimistic about the potential delay of PAMA, which could positively impact revenue [53] - The company is confident in its growth momentum, driven by utilization, consumer engagement, and advanced diagnostics [137] Other Important Information - The company is preparing for potential impacts from the expiration of ACA subsidies, estimating a 30 basis point impact on volumes and revenue next year [70] - The company is also focused on evidence generation and operational rigor to drive adoption of new tests like Haystack [91] Q&A Session Summary Question: Can you discuss the consumer channel and its growth? - The consumer channel is growing nicely, with expectations of reaching $250 million in revenue in the future, currently growing at 35% year-over-year [8] Question: How is the advanced diagnostics segment performing? - Advanced diagnostics testing areas are growing in the low double digits, contributing significantly to overall revenue [12] Question: What are the expectations for Project Nova? - Project Nova is expected to incur costs of $250-$310 million, with benefits anticipated starting in 2027 [42][50] Question: How does management view the potential impact of PAMA? - Management is cautiously optimistic about a potential delay in PAMA, which could mitigate revenue impacts [53] Question: What are the key growth drivers for the company? - Key growth drivers include strong utilization, consumer engagement, and advanced diagnostics [137]